MBMichael Belshan

Michael Belshan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Belshan has a total of 68 co-authors. Here are the top co-authors by number of shared publications:

  • Christian J. Madson

    Department of Medical Microbiology and Immunology, Creighton University, Omaha, NE, USA

    5 shared publications
  • Pawel Ciborowski

    Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA

    4 shared publications
  • Jason DeBoer

    Department of Medical Microbiology and Immunology, Creighton University, 2500 California Plaza, Omaha, NE 68178, USA

    3 shared publications
  • Joseph W. George

    Creighton Univ, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA

    3 shared publications
  • Yan Li

    Department of Medical Microbiology and Immunology, Creighton University, 2500 California Plaza, Omaha, NE 68178, USA

    3 shared publications
  • Alexander Holbrook

    Creighton Univ, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA

    2 shared publications

Latest Publications

  • Corrigendum to “Discovery of candidate HIV-1 latency biomarkers using an OMICs approach” [Virology (2021 Jun) 558 86–95, Epub 2021 Mar 11]

    by Michael Belsham, Alexander Holbrook, Joseph W. George, Hannah E. Durant, Michael Callahan, Spencer Jaquet, John T. West, Jacob Siedlik, Pawel Ciborowski

  • Open Access

    Characterization of Ag-Ion Releasing Zeolite Filled 3D Printed Resins

    by Marian O. Pacho, Dylan Deeney, Emily A. Johnson, Bryanna N. Bravo, Kishen Patel, Mark A. Latta, Michael A. Belshan, Stephen M. Gross

    There has been profound growth in the use of 3D printed materials in dentistry in general, including orthodontics. The opportunity to impart antimicrobial properties to 3D printed parts from existing resins requires the capability of forming a stable colloid incorporating antimicrobial fillers. The objective of this research was to characterize a colloid consisting of a 3D printable resin mixed with Ag-ion releasing zeolites and fumed silica to create 3D printed parts with antiviral properties. The final composite was tested for antiviral properties against SARS-CoV-2 and HIV-1. Antiviral activity was measured in terms of the half-life of SARS-CoV-2 and HIV-1 on the composite surface. The inclusion of the zeolite did not interfere with the kinetics measured on the surface of the ATR crystal. While the depth of cure, measured following ISO4049 guidelines, was reduced from 3.8 mm to 1.4 mm in 5 s, this greatly exceeded the resolution required for 3D printing. The colloid was stable for at least 6 months and the rheological behavior was dependent upon the fumed silica loading. The inclusion of zeolites and fumed silica significantly increased the flexural strength of the composite as measured by a 3 point bend test. The composite released approximately 2500 μg/L of silver ion per gram of composite as determined by potentiometry. There was a significant reduction of the average half-life of SARS-CoV-2 (1.9 fold) and HIV-1 (2.7 fold) on the surface of the composite. The inclusion of Ag-ion releasing zeolites into 3D-printable resin can result in stable colloids that generate composites with improved mechanical properties and antiviral properties.


  • Open Access

    Targeted Immuno-Antiretroviral to Promote Dual Protection against HIV: A Proof-of-Concept Study

    by Subhra Mandal, Shawnalyn W. Sunagawa, Pavan Kumar Prathipati, Michael Belshan, Annemarie Shibata, Christopher J. Destache

    The C–C motif chemokine receptor-5 (CCR5) expression on the T-cell surface is the prime barrier to HIV/AIDS eradication, as it promotes both active human immunodeficiency virus (HIV)-infection and latency; however, antiretrovirals (ARVs) suppress plasma viral loads to non-detectable levels. Keeping this in mind, we strategically designed a targeted ARVs-loaded nanoformulation that targets CCR5 expressing T-cells (e.g., CD4+ cells). Conceptually, CCR5-blocking and targeted ARV delivery would be a dual protection strategy to prevent HIV infection. For targeting CCR5+ T-cells, the nanoformulation was surface conjugated with anti-CCR5 monoclonal antibodies (CCR5 mAb) and loaded with dolutegravir+tenofovir alafenamide (D+T) ARVs to block HIV replication. The result demonstrated that the targeted-ARV nanoparticle’s multimeric CCR5 binding property improved its antigen-binding affinity, prolonged receptor binding, and ARV intracellular retention. Further, nanoformulation demonstrated high binding affinity to CCR5 expressing CD4+ cells, monocytes, and other CCR5+ T-cells. Finally, the short-term pre-exposure prophylaxis study demonstrated that prolonged CCR5 blockage and ARV presence further induced a “protective immune phenotype” with a boosted T-helper (Th), temporary memory (TM), and effector (E) sub-population. The proof-of-concept study that the targeted-ARV nanoformulation dual-action mechanism could provide a multifactorial solution toward achieving HIV “functional cure.”


  • Open Access

    Epidemiologic and Genomic Analysis of the Severe Acute Respiratory Syndrome Coronavirus 2 Epidemic in the Nebraska Region of the United States, March 2020–2021

    by Jacob A. Siedlik, Cynthia J. Watson, Morgan A. Raine, Anne V. Cheng, Richard V. Goering, Holly A. F. Stessman, Michael Belshan

    COVID-19 emerged at varying intervals in different regions of the United States in 2020. This report details the epidemiologic and genetic evolution of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first year of the epidemic in the state of Nebraska using data collected from the Creighton Catholic Health Initiatives (CHI) health system. Statistical modelling identified age, gender, and previous history of diabetes and/or stroke as significant risk factors associated with mortality in COVID-19 patients. In parallel, the viral genomes of over 1,000 samples were sequenced. The overall rate of viral variation in the population was 0.07 mutations/day. Genetically, the first 9 months of the outbreak, which include the initial outbreak, a small surge in August and a major outbreak in November 2020 were primarily characterized by B.1. lineage viruses. In early 2021, the United Kingdom variant (B.1.1.7 or alpha) quickly became the dominant variant. Notably, surveillance of non-consensus variants detected B.1.1.7 defining mutations months earlier in Fall 2020. This work provides insights into the regional variance and evolution of SARS-CoV-2 in the Nebraska region during the first year of the pandemic.

  • Discovery of candidate HIV-1 latency biomarkers using an OMICs approach

    by Michael Belshan, Alexander Holbrook, Joseph W. George, Hannah E. Durant, Michael Callahan, Spencer Jaquet, John T. West, Jacob Siedlik, Pawel Ciborowski


  • Open Access

    Targeted immuno-antiretroviral HIV therapeutic approach to provide dual protection and boosts cellular immunity: A proof-of-concept study

    by Subhra Mandal, Shawnalyn W. Sunagawa, Pavan Kumar Prathipati, Michael Belshan, Annemarie Shibata, Christopher J. Destache

    Human immunodeficiency virus (HIV)-infected active and latent CCR5 expressing long-lived T-cells are the primary barrier to HIV/AIDS eradication. Broadly neutralizing antibodies and latency-reversing agents are the two most promising strategies emerging to achieve ‘functional cure’ against HIV infection. Antiretrovirals (ARVs) have shown to suppress plasma viral loads to non-detectable levels and above strategies have demonstrated a ‘functional cure’ against HIV infection is achievable. Both the above strategies are effective at inducing direct or immune-mediated cell death of latent HIV+ T-cells but have shown respective limitations. In this study, we designed a novel targeted ARVs-loaded nanoformulation that combines the CCR5 monoclonal antibody and antiretroviral drugs (ARV) as a dual protection strategy to promote HIV ‘functional cure’. The modified CCR5 monoclonal antibody (xfR5 mAb) surface-coated dolutegravir (DTG) and tenofovir alafenamide (TAF) loaded nanoformulation (xfR5-D+T NPs) were uniformly sized 1/2 ). The multivalent and sustained drug release properties of xfR5-D+T NPs enhance the protection efficiency against HIV by approximately 12, 3, and 5 times compared to naïve xfR5 mAb, D+T NP alone, and xfR5 NPs, respectively. Further, the nanoformulation demonstrated high binding-affinity to CCR5 expressing CD4+ cells, monocytes, and other HIV prone/latent T-cells by 25, 2, and 2 times, respectively. Further, the xfR5-D+T NPs during short-term pre-exposure prophylaxis induced a protective immunophenotype, i.e., boosted T-helper (T h ), temporary memory (TM), and effector (E) sub-population. Moreover, treatment with xfR5-D+T NPs to HIV-infected T-cells induced a defensive/activated immunophenotype i.e., boosted naïve, T h , boosted central memory, TM, EM, E, and activated cytotoxic T-cells population. Therefore, this dual-action targeted mAb-ARV loaded nanoformulation could potentially become a multifactorial/multilayered solution to achieve a “functional cure.”

  • Proteomic profiling of HIV-infected T-cells by SWATH mass spectrometry

    by Jason DeBoer, Melinda S. Wojtkiewicz, Nicole Haverland, Yan Li, Emma Harwood, Emily Leshen, Joseph W. George, Pawel Ciborowski, Michael Belshan


  • Open Access

    NF45 and NF90 Bind HIV-1 RNA and Modulate HIV Gene Expression

    by Yan Li, Michael Belshan

    A previous proteomic screen in our laboratory identified nuclear factor 45 (NF45) and nuclear factor 90 (NF90) as potential cellular factors involved in human immunodeficiency virus type 1 (HIV-1) replication. Both are RNA binding proteins that regulate gene expression; and NF90 has been shown to regulate the expression of cyclin T1 which is required for Tat-dependent trans-activation of viral gene expression. In this study the roles of NF45 and NF90 in HIV replication were investigated through overexpression studies. Ectopic expression of either factor potentiated HIV infection, gene expression, and virus production. Deletion of the RNA binding domains of NF45 and NF90 diminished the enhancement of HIV infection and gene expression. Both proteins were found to interact with the HIV RNA. RNA decay assays demonstrated that NF90, but not NF45, increased the half-life of the HIV RNA. Overall, these studies indicate that both NF45 and NF90 potentiate HIV infection through their RNA binding domains.


  • Cyclophilin B enhances HIV-1 infection

    by Jason DeBoer, Christian J. Madson, Michael Belshan


  • Investigation of the HIV‐1 matrix interactome during virus replication

    by Yan Li, Kristin M. Frederick, Nicole A. Haverland, Pawel Ciborowski, Michael Belshan

    Purpose: Like all viruses, human immunodeficiency virus type 1 (HIV‐1) requires host cellular factors for productive replication. Identification of these factors may lead to the development of novel cell‐based inhibitors.Experimental design: A Strep‐tag was inserted into the C‐terminus of the matrix (MA) region of the HIV‐1 gag gene. The resultant virus was replication competent and used to infect Jurkat T‐cells. MA complexes were affinity purified with Strep‐Tactin agarose. Protein quantification was performed using sequential window acquisition of all theoretical fragment ion spectra (SWATH) MS, data were log2‐transformed, and Student t‐tests with Bonferroni correction used to determine statistical significance. Several candidate proteins were validated by immunoblot and investigated for their role in virus infection by siRNA knockdown assays.Results: A total of 17 proteins were found to be statistically different between the infected versus uninfected and untagged control samples. X‐ray repair cross‐complementing protein 6 (Ku70), X‐ray repair cross‐complementing protein 5 (Ku80), and Y‐box binding protein 1 (YB‐1) were confirmed to interact with MA by immunoblot. Knockdown of two candidates, EZRIN and Y‐box binding protein 1, enhanced HIV infection in vitro.Conclusions and clinical relevance: The Strep‐tag allowed for the capture of viral protein complexes in the context of virus replication. Several previously described factors were identified and at least two candidate proteins were found to play a role in HIV‐1 infection. These data further increase our understanding of HIV host –cell interactions.